KR20090060997A - Snac(살카프로제이트 나트륨)의 제조 방법 - Google Patents
Snac(살카프로제이트 나트륨)의 제조 방법 Download PDFInfo
- Publication number
- KR20090060997A KR20090060997A KR1020097004631A KR20097004631A KR20090060997A KR 20090060997 A KR20090060997 A KR 20090060997A KR 1020097004631 A KR1020097004631 A KR 1020097004631A KR 20097004631 A KR20097004631 A KR 20097004631A KR 20090060997 A KR20090060997 A KR 20090060997A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- hydroxybenzoyl
- amino
- sodium
- dioxo
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 title description 37
- 238000004519 manufacturing process Methods 0.000 title description 6
- 230000008569 process Effects 0.000 title description 5
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 45
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- -1 3-benzoxazinyloctanoate ethyl ester Chemical compound 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
- RQSYZQMFSKGZTL-UHFFFAOYSA-N ethyl 2-(2,4-dioxo-1,3-benzoxazin-5-yl)octanoate Chemical compound O1C(=O)NC(=O)C2=C1C=CC=C2C(C(=O)OCC)CCCCCC RQSYZQMFSKGZTL-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 229960005480 sodium caprylate Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 239000012535 impurity Substances 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 abstract description 5
- 159000000000 sodium salts Chemical class 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 4
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 abstract 2
- 238000010931 ester hydrolysis Methods 0.000 abstract 2
- 229960002446 octanoic acid Drugs 0.000 abstract 2
- 229940122361 Bisphosphonate Drugs 0.000 description 56
- 150000004663 bisphosphonates Chemical class 0.000 description 56
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 229940015872 ibandronate Drugs 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 7
- 208000037147 Hypercalcaemia Diseases 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000148 hypercalcaemia Effects 0.000 description 6
- 208000030915 hypercalcemia disease Diseases 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 229940069328 povidone Drugs 0.000 description 6
- 208000036631 Metastatic pain Diseases 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940028101 boniva Drugs 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- SUSNCCGSNPFNOS-UHFFFAOYSA-N ethyl 2-(2H-1,3-benzoxazin-2-yl)-3,4-dioxooctanoate Chemical compound C(C)OC(C(C(C(CCCC)=O)=O)C1OC2=C(C=N1)C=CC=C2)=O SUSNCCGSNPFNOS-UHFFFAOYSA-N 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CZYWHNTUXNGDGR-UHFFFAOYSA-L Pamidronate disodium Chemical compound O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CZYWHNTUXNGDGR-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940037127 actonel Drugs 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- SKUHWSDHMJMHIW-UHFFFAOYSA-L disodium;[(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)SC1=CC=C(Cl)C=C1 SKUHWSDHMJMHIW-UHFFFAOYSA-L 0.000 description 1
- ZZFKAZHZSSJSSE-UHFFFAOYSA-L disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate;hydrate Chemical compound O.[Na+].[Na+].OP(O)(=O)C(P([O-])([O-])=O)NC1CCCCCC1 ZZFKAZHZSSJSSE-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940001490 fosamax Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229950006971 incadronic acid Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940058213 medronate Drugs 0.000 description 1
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940112726 skelid Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000004684 trihydrates Chemical group 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/04—Sodium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Claims (9)
- 2,4-다이옥소-1,3-벤즈옥사진일옥탄산 에틸 에스터를 수산화 나트륨, 물, 및 에틸렌다이아민 테트라아세트산, 아스코르브산, NaHSO3 및 트라이페닐포스파인으로 이루어진 군으로부터 선택된 성분과 혼합함으로써 2,4-다이옥소-1,3-벤즈옥사진일옥탄산 에틸 에스터를 가수분해시키는 단계를 포함하는, N-(8-[2-하이드록시벤조일]-아미노) 카프릴산의 합성 방법.
- 2,4-다이옥소-1,3-벤즈옥사진일옥탄산 에틸 에스터를 수산화 나트륨 및 미리 비등된 물과 혼합함으로써 2,4-다이옥소-1,3-벤즈옥사진일옥탄산 에틸 에스터를 가수분해시키는 단계를 포함하는, N-(8-[2-하이드록시벤조일]-아미노) 카프릴산의 합성 방법.
- 제 1 항에 있어서,수산화 나트륨, 물, 및 에틸렌다이아민 테트라아세트산, 아스코르브산, NaHSO3 및 트라이페닐포스파인으로 이루어진 군으로부터 선택된 성분과 혼합된 2,4-다이옥소-1,3-벤즈옥사진일옥탄산 에틸 에스터를, 아세톤 및 염산과 혼합하는 단계를 추가로 포함하는, 방법.
- 제 2 항에 있어서,수산화 나트륨 및 미리 비등된 물과 혼합된 2,4-다이옥소-1,3-벤즈옥사진일옥탄산 에틸 에스터에, 아세톤 및 염산을 첨가하는 단계를 추가로 포함하는, 방법.
- 2-프로판올 중에 현탁된 N-(8-[2-하이드록시벤조일]-아미노) 카프릴산을 수산화 나트륨 수용액과 혼합하여 N-(8-[2-하이드록시벤조일]-아미노) 카프릴산 나트륨 염의 용액을 형성하는 단계를 포함하는, N-(8-[2-하이드록시벤조일]-아미노) 카프릴산 나트륨 염의 합성 방법.
- 제 5 항에 있어서,추가의 2-프로판올을 상기 용액에 첨가하는 단계; 상기 N-(8-[2-하이드록시벤조일]-아미노) 카프릴산 나트륨 염의 용액을 결정성 N-(8-[2-하이드록시벤조일]-아미노) 카프릴산 나트륨 염으로 시딩(seeding)하여 상기 N-(8-[2-하이드록시벤조일]-아미노) 카프릴산 나트륨 염을 상기 용액으로부터 침전시키는 단계; 및 이어서, 추가의 2-프로판올을 상기 용액에 더 첨가하는 단계를 추가로 포함하는, 방법.
- 제 5 항에 있어서,상기 결정성 N-(8-[2-하이드록시벤조일]-아미노) 카프릴산 나트륨 염이 무수 N-(8-[2-하이드록시벤조일]-아미노) 카프릴산 나트륨 염인, 방법.
- 제 1 항에 있어서,상기 N-(8-[2-하이드록시벤조일]-아미노) 카프릴산이, 에틸렌다이아민 테트라아세트산, 아스코르브산, NaHSO3 및 트라이페닐포스파인 중 하나 이상의 부재 하에 상기 2,4-다이옥소-1,3-벤즈옥사진일옥탄산 에틸 에스터를 가수분해시키는 경우보다 분홍색 착색체(pink body)를 덜 함유하는, 방법.
- 제 1 항에 있어서,상기 N-(8-[2-하이드록시벤조일]-아미노) 카프릴산이, 미리 비등되지 않은 물 중에서 상기 2,4-다이옥소-1,3-벤즈옥사진일옥탄산 에틸 에스터를 가수분해시키는 경우보다 분홍색 착색체를 덜 함유하는, 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84277506P | 2006-09-07 | 2006-09-07 | |
US60/842,775 | 2006-09-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090060997A true KR20090060997A (ko) | 2009-06-15 |
KR101081149B1 KR101081149B1 (ko) | 2011-11-07 |
Family
ID=38702068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097004631A KR101081149B1 (ko) | 2006-09-07 | 2007-08-30 | Snac(살카프로제이트 나트륨)의 제조 방법 |
Country Status (12)
Country | Link |
---|---|
US (3) | US10875826B2 (ko) |
EP (1) | EP2064175B1 (ko) |
JP (1) | JP5021033B2 (ko) |
KR (1) | KR101081149B1 (ko) |
CN (1) | CN101506147B (ko) |
AU (1) | AU2007293916B2 (ko) |
BR (1) | BRPI0716539A2 (ko) |
CA (1) | CA2662080C (ko) |
ES (1) | ES2498519T3 (ko) |
IL (1) | IL197014A (ko) |
MX (1) | MX2009002121A (ko) |
WO (1) | WO2008028859A1 (ko) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895777B2 (en) * | 2006-08-31 | 2014-11-25 | Emisphere Technologies Inc | Compounds and compositions for delivering active agents |
KR101081149B1 (ko) * | 2006-09-07 | 2011-11-07 | 에미스페어 테크놀로지스, 인코포레이티드 | Snac(살카프로제이트 나트륨)의 제조 방법 |
SI3326620T1 (sl) | 2010-12-16 | 2020-07-31 | Novo Nordisk A/S | Trdne sestave, ki vsebujejo agonist GLP-1 in sol N-(8-(2-hidroksibenzoil)amino)kaprilne kisline |
JP6022538B2 (ja) | 2011-04-12 | 2016-11-09 | ノヴォ ノルディスク アー/エス | 二重アシル化されたglp−1誘導体 |
CN104203221A (zh) | 2012-03-22 | 2014-12-10 | 诺和诺德A/S(股份有限公司) | 包含递送剂的组合物及其制备 |
PT2827845T (pt) | 2012-03-22 | 2019-03-29 | Novo Nordisk As | Composições compreendendo um agente de entrega e sua preparação |
EP4324475A1 (en) | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
SI2991671T1 (sl) | 2013-05-02 | 2018-10-30 | Novo Nordisk A/S | Peroralno odmerjanje spojin GLP-1 |
ES2820600T3 (es) * | 2014-09-25 | 2021-04-21 | Daikin Ind Ltd | Composición que comprende HFC y HFO |
CN105566141B (zh) * | 2015-12-17 | 2018-01-26 | 蚌埠丰原医药科技发展有限公司 | 一种门冬氨酸缩合物的制备方法 |
TWI797133B (zh) | 2017-06-09 | 2023-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | 用於經口投予的固體組成物 |
MA49617A (fr) | 2017-07-19 | 2020-05-27 | Novo Nordisk As | Analogues d'egf(a), préparation, formulations et utilisations associées |
MX2020007598A (es) | 2018-02-02 | 2020-09-03 | Novo Nordisk As | Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante. |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
CN108689876B (zh) * | 2018-06-28 | 2020-11-27 | 苏州东南药业股份有限公司 | 一种8-(2-羟基苯甲酰胺基)辛酸钠的制备方法 |
KR20220046565A (ko) | 2019-08-07 | 2022-04-14 | 노보 노르디스크 에이/에스 | Egf(a) 유도체 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물 |
WO2021043971A1 (en) | 2019-09-06 | 2021-03-11 | Novo Nordisk A/S | Method and equipment for fractionation of granules for use in pharmaceutical compositions |
BR112022007721A2 (pt) | 2019-11-06 | 2022-07-12 | Novo Nordisk As | Método para o tratamento da demência |
JP2023500031A (ja) | 2019-11-07 | 2023-01-04 | ノヴォ ノルディスク アー/エス | Pcsk9阻害剤およびn-(8-(2-ヒドロキシベンゾイル)アミノ)カプリル酸の塩を含む固形組成物 |
EP4054536A1 (en) | 2019-11-07 | 2022-09-14 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
IT202000003251A1 (it) | 2020-02-18 | 2021-08-18 | Dipharma Francis Srl | Preparazione di un analgesico non steroideo |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
US20230165939A1 (en) | 2020-04-29 | 2023-06-01 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
WO2021238088A1 (zh) | 2020-05-29 | 2021-12-02 | 杭州先为达生物科技有限公司 | N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途 |
CN113735733B (zh) * | 2020-05-29 | 2024-04-26 | 杭州先为达生物科技股份有限公司 | N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途 |
JPWO2022080294A1 (ko) | 2020-10-16 | 2022-04-21 | ||
WO2022162132A1 (en) | 2021-01-29 | 2022-08-04 | Novo Nordisk A/S | Novel synthesis of salcaprozic acid by amide formation |
EP4323330A1 (en) | 2021-04-16 | 2024-02-21 | Navinta III Inc | Process for the preparation of highly pure salcaprozic acid and pharmaceutically acceptable salts thereof |
US11667614B2 (en) | 2021-04-16 | 2023-06-06 | Navinta III Inc. | Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof |
BR112023021766A2 (pt) | 2021-04-22 | 2024-01-23 | Civi Biopharma Inc | Dispensação oral de oligonucleotídeo |
WO2022264166A1 (en) | 2021-06-14 | 2022-12-22 | Mylan Laboratories Limited | Process for the preparation of pure salcaprozate sodium |
WO2022268213A1 (zh) | 2021-06-25 | 2022-12-29 | 甘李药业股份有限公司 | 含glp-1化合物的药物组合物 |
CN117979958A (zh) | 2021-07-15 | 2024-05-03 | 诺和诺德股份有限公司 | 包含n-(8-(2-羟基苯甲酰基)氨基)辛酸盐的片剂 |
WO2023285581A1 (en) | 2021-07-16 | 2023-01-19 | Novo Nordisk A/S | Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
CN115160178A (zh) * | 2022-07-29 | 2022-10-11 | 成都普康唯新生物科技有限公司 | 一种8-(2-羟基苯甲酰胺基)辛酸钠无水晶型的制备方法 |
CN115108936A (zh) * | 2022-07-29 | 2022-09-27 | 成都普康唯新生物科技有限公司 | 无水体系制备8-(2-羟基苯甲酰胺基)辛酸钠无水晶型的方法 |
WO2024110614A1 (en) | 2022-11-25 | 2024-05-30 | Novo Nordisk A/S | Oral administration of peptide therapeutics, such as glp-1 |
CN117466765B (zh) * | 2023-12-27 | 2024-03-15 | 成都道合尔医药技术有限公司 | 8-(2-羟基苯甲酰胺基)辛酸钠及其合成方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3840570A (en) | 1970-12-07 | 1974-10-08 | Procter & Gamble | Process for preparing sterols from tall oil pitch |
DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US5717109A (en) | 1994-09-08 | 1998-02-10 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
WO1997010197A1 (en) | 1995-09-11 | 1997-03-20 | Emisphere Technologies, Inc. | METHOD FOR PREPARING φ-AMINOALKANOIC ACID DERIVATIVES FROM CYCLOALKANONES |
JPH09188661A (ja) * | 1996-01-10 | 1997-07-22 | Kao Corp | ポリオキシアルキレン脂肪酸アミド硫酸エステル塩の製造方法 |
US6096273A (en) | 1996-11-05 | 2000-08-01 | Clinical Micro Sensors | Electrodes linked via conductive oligomers to nucleic acids |
US7381525B1 (en) | 1997-03-07 | 2008-06-03 | Clinical Micro Sensors, Inc. | AC/DC voltage apparatus for detection of nucleic acids |
US7393645B2 (en) | 1996-11-05 | 2008-07-01 | Clinical Micro Sensors, Inc. | Compositions for the electronic detection of analytes utilizing monolayers |
WO1999014238A1 (en) | 1997-09-18 | 1999-03-25 | Hyundai Pharm. Ind. Co., Ltd. | Process for the preparation of calcitonin |
DE60023841T2 (de) * | 1999-02-05 | 2006-05-24 | Emisphere Technologies, Inc. | Verfahren zur herstellung alkylierter salicylamide |
WO2000059863A1 (en) * | 1999-04-05 | 2000-10-12 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
US6900344B2 (en) | 2000-03-21 | 2005-05-31 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
US6949577B2 (en) | 2000-09-13 | 2005-09-27 | Pfizer, Inc. | Pharmaceuticals |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
JP4494020B2 (ja) | 2002-03-15 | 2010-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Hivインテグラーゼ阻害剤として有用なn−(置換ベンジル)−8−ヒドロキシ−1,6−ナフチリジン−7−カルボキサミド |
CN100418948C (zh) | 2003-07-15 | 2008-09-17 | 麦克公司 | 羟基吡啶cgrp受体抗拮抗剂 |
US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
JP2005298463A (ja) * | 2004-04-07 | 2005-10-27 | Matsumoto Yushi Seiyaku Co Ltd | 開環重合方法 |
ES2879880T3 (es) | 2004-05-06 | 2021-11-23 | Novo Nordisk North America Operations As | Formas polimórficas cristalinas del n-[8-(2-hidroxibenzoil)amino]caprilato monosódico |
PE20060653A1 (es) | 2004-08-31 | 2006-09-27 | Glaxo Group Ltd | Derivados triciclicos condensados como moduladores del receptor 5-ht1 |
JP5011683B2 (ja) * | 2004-09-06 | 2012-08-29 | Dic株式会社 | 多価ヒドロキシ化合物、エポキシ樹脂、及びそれらの製造法、エポキシ樹脂組成物と硬化物 |
WO2006067587A2 (en) | 2004-12-22 | 2006-06-29 | Pfizer Limited | Nonnucleoside inhibitors of hiv-1 reverse transcriptase |
US7705142B2 (en) | 2005-03-29 | 2010-04-27 | Hetero Drugs Limited | Process for the preparation of cefixime |
CN101258132B (zh) | 2005-12-14 | 2012-04-25 | 江苏恒瑞医药股份有限公司 | 用作金属蛋白酶抑制剂的(2,5-二酮咪唑啉-1-基)-n-羟基-乙酰胺 |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
KR101081149B1 (ko) * | 2006-09-07 | 2011-11-07 | 에미스페어 테크놀로지스, 인코포레이티드 | Snac(살카프로제이트 나트륨)의 제조 방법 |
FR2912145B1 (fr) | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
EP2167477B1 (en) | 2007-06-27 | 2013-02-27 | Mylan Laboratories Limited | Process for preparing pure valsartan |
CN101796064B (zh) | 2007-07-31 | 2014-04-16 | 株式会社糖锁工学研究所 | 肽的制备方法 |
CN101367750B (zh) | 2007-08-14 | 2012-05-23 | 中国人民解放军军事医学科学院毒物药物研究所 | (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途 |
-
2007
- 2007-08-30 KR KR1020097004631A patent/KR101081149B1/ko active IP Right Grant
- 2007-08-30 MX MX2009002121A patent/MX2009002121A/es active IP Right Grant
- 2007-08-30 WO PCT/EP2007/059037 patent/WO2008028859A1/en active Application Filing
- 2007-08-30 JP JP2009527117A patent/JP5021033B2/ja active Active
- 2007-08-30 CN CN2007800316394A patent/CN101506147B/zh active Active
- 2007-08-30 BR BRPI0716539A patent/BRPI0716539A2/pt not_active Application Discontinuation
- 2007-08-30 EP EP07803046.7A patent/EP2064175B1/en active Active
- 2007-08-30 ES ES07803046.7T patent/ES2498519T3/es active Active
- 2007-08-30 AU AU2007293916A patent/AU2007293916B2/en active Active
- 2007-08-30 US US16/490,424 patent/US10875826B2/en active Active
- 2007-08-30 US US11/847,415 patent/US7544833B2/en active Active
- 2007-08-30 CA CA2662080A patent/CA2662080C/en not_active Expired - Fee Related
-
2009
- 2009-02-12 IL IL197014A patent/IL197014A/en active IP Right Grant
-
2020
- 2020-11-23 US US17/101,375 patent/US20210070691A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2007293916A1 (en) | 2008-03-13 |
CN101506147A (zh) | 2009-08-12 |
BRPI0716539A2 (pt) | 2016-11-01 |
EP2064175A1 (en) | 2009-06-03 |
ES2498519T3 (es) | 2014-09-24 |
US20080064890A1 (en) | 2008-03-13 |
JP5021033B2 (ja) | 2012-09-05 |
US20210070691A1 (en) | 2021-03-11 |
AU2007293916B2 (en) | 2011-02-03 |
WO2008028859A1 (en) | 2008-03-13 |
US10875826B2 (en) | 2020-12-29 |
CA2662080A1 (en) | 2008-03-13 |
KR101081149B1 (ko) | 2011-11-07 |
CA2662080C (en) | 2012-07-17 |
IL197014A0 (en) | 2009-11-18 |
US20200071263A1 (en) | 2020-03-05 |
CN101506147B (zh) | 2012-03-21 |
MX2009002121A (es) | 2009-05-20 |
EP2064175B1 (en) | 2014-08-06 |
US7544833B2 (en) | 2009-06-09 |
IL197014A (en) | 2013-01-31 |
JP2010502667A (ja) | 2010-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101081149B1 (ko) | Snac(살카프로제이트 나트륨)의 제조 방법 | |
JP6932227B2 (ja) | カルビドパおよびl−ドーパプロドラッグならびにそれらの使用方法 | |
WO2018096504A1 (en) | Cbd prodrugs, compositions, and methods of administering cbd and cbd prodrugs | |
EP1131327B1 (en) | Prostaglandin conjugates for treating or preventing bone diseases | |
SK11002002A3 (sk) | Proces na selektívnu produkciu hemipentahydrátu monohydrátu sodnej soli kyseliny 3-pyridyl-1-hydroxyetylidén-1,1- bifosfónovej a farmaceutický prostriedok | |
CN105153122A (zh) | [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用 | |
CZ304038B6 (cs) | Zpusob výroby geminálních bisfosfonátu | |
TW202037597A (zh) | 用於製備丁基原啡因之方法 | |
US20140080875A1 (en) | 3,4-diaminopyridine tartrate and phosphate, pharmaceutical compositions and uses thereof | |
US20210323908A1 (en) | Process for producing tca cycle intermediate conjugates | |
US20060148832A1 (en) | Use of 2-amino-2h-quinazoline derivatives for producing therapeutic agents | |
US7786168B2 (en) | Phenolic acid salts of gabapentin in solid dosage forms and methods of use | |
TW202024038A (zh) | 靶向突變哺乳動物蛋白質之小分子 | |
WO2022020247A1 (en) | Small molecule correctors of mammalian slc6a8 function | |
WO2020061476A1 (en) | Small molecules targeting mutant mammalian proteins | |
CN111233933A (zh) | 一种米诺膦酸二聚体的合成方法 | |
EP3315493A1 (en) | Phenyl amino pyrimidine compound or polymorph of salt thereof | |
WO2007082472A1 (en) | Anti-infective quinolone compound, preparation method thereof and use thereof | |
CN111494395B (zh) | 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途 | |
WO2001030788A1 (en) | Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use | |
WO2021207577A1 (en) | Process for producing tca cycle intermediate conjugates and polymorphs of a tca cycle intermediate conjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141030 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161028 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170929 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180928 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190924 Year of fee payment: 9 |